Oyster Point Pharma CEO Jeff Nau sheds some light on the new dry eye start-up, which is tapping much of the leadership and investment team that made Oculeve successful. He also talks about his own experiences leading high-profile clinical programs at Ophthotech and Genentech. What lessons will he bring into his new CEO role?